DUBLIN--(BUSINESS WIRE)--The "Eosinophilic Esophagitis- Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report outlays comprehensive insights of the present scenario and growth prospects across Eosinophilic Esophagitis.
A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 10+ products along with 10+ companies involved.
Products Covered by Phase
- Phase III and Phase II
- Inactive (Dormant and Discontinued)
Scope of the Report
- Provides an overview of therapeutic pipeline activity for Eosinophilic Esophagitis across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Eosinophilic Esophagitis therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
- Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
- Coverage of dormant and discontinued pipeline projects across Eosinophilic Esophagitis
- Adare Pharmaceuticals
- Atopix Therapeutics
- Biotica Pharmaceuticals
- Calypso Biotech
- DBV Technologies
- Quorum Innovations
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jdlqq4/eosinophilic?w=4